|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0275 AUD | +10.00% |
|
-.--% | -.--% |
| Feb. 26 | Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| 2023 | Exopharm to Cut CEO Role Amid Cost Reductions | MT |
Exopharm Limited announced a private placement of Convertible Note for proceeds of AUD 600,000 on February 13, 2023. The note contains no interest. The transaction is subject to Shareholder and Australian stock exchange approvals.
The Convertible Note converts at a 20% discount to the Entitlement Issue price, subject to the full Entitlement Issue being completed.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 3.15M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
EXOPHARM LIMITED 
